Dopamine

Evidence Level: L5

Predicted Indications: 10

Dopamine
Dopamine: From Vasopressor Use in Shock to Postural Orthostatic Tachycardia Syndrome (POTS)

## Pharmacist Assessment Report

Dopamine: From Vasopressor Use in Shock to Postural Orthostatic Tachycardia Syndrome (POTS)

One-Sentence Summary

Dopamine (DrugBank DB00988) is an endogenous catecholamine classically used clinically as a vasopressor/inotropic agent in shock and severe hypotension — no formal EU-approved indication text is available in this evidence pack. The TxGNN model predicts a possible new role in Postural Orthostatic Tachycardia Syndrome (POTS), currently supported by 6 clinical trials and 7 publications, though the trials found are largely mechanistic/physiological studies of endogenous renal dopamine rather than interventional trials testing dopamine as a POTS treatment.

Quick Overview

Item	Content
Original Indication	Not available in evidence pack (`original_indications` is empty). Based on general pharmacological knowledge, dopamine hydrochloride is used as a vasopressor/inotropic agent in shock and hypotension — TFDA/EMA-specific indication wording is a documented data gap (DG001)
Predicted New Indication	Postural Orthostatic Tachycardia Syndrome (POTS)
TxGNN Prediction Score	88.00% (raw score 0.8800; model rank 82,652)
Evidence Level	L4 (mechanistic/observational human studies; no direct interventional evidence of dopamine treating POTS)
EU Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this candidate (original_moa: [Data Gap]). Based on general pharmacological knowledge, dopamine is an endogenous catecholamine and biosynthetic precursor of norepinephrine; as dopamine hydrochloride injection, it is used for its vasopressor and positive inotropic effects via dopaminergic (D1/D2) and adrenergic (α/β) receptor activity, supporting blood pressure and cardiac output in shock states. This receptor pharmacology also plays a physiological role in autonomic regulation of heart rate, vascular tone, and renal sodium handling.

POTS is a disorder of autonomic/sympathetic dysregulation, frequently accompanied by impaired plasma volume expansion and abnormal renal sodium handling — processes in which the renal dopaminergic system is known to participate. This provides a plausible biological rationale for TxGNN’s association between dopamine and POTS: both the original (presumed) use and the predicted indication converge on sympathetic nervous system and vascular/volume regulation.

However, it is important to note that the clinical trial evidence retrieved for this candidate largely investigates the endogenous renal dopaminergic system in POTS patients (e.g., using carbidopa to suppress dopamine synthesis, measuring urinary dopamine excretion, or studying dietary dopamine precursors) rather than administering dopamine itself as a therapeutic intervention for POTS. This is a meaningful distinction: the evidence supports a mechanistic link between the dopaminergic pathway and POTS pathophysiology, but does not directly demonstrate therapeutic benefit of dopamine administration in POTS patients.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00685919	Phase 2/3	Completed	32	Investigated how suppressing renal dopamine synthesis (via carbidopa) affects urinary sodium excretion in POTS patients vs. healthy volunteers — a mechanistic study, not a dopamine treatment trial
NCT01563107	N/A	Completed	38	Examined how dietary sodium intake affects urinary sodium and dopamine excretion in POTS patients, exploring renal dopaminergic involvement in plasma volume regulation
NCT01547117	N/A	Completed	38	Studied whether high-sodium diet appropriately expands plasma volume in POTS and how renin-angiotensin-aldosterone and renal dopamine respond
NCT01064739	Early Phase 1	Completed	14	Characterized diuretic effects of dietary catecholamine sources (e.g., fava beans, which raise endogenous dopamine) on renal sodium handling
NCT00001418	N/A	Completed	335	Used PET imaging (fluorodopamine) to measure sympathetic nervous system activity in patients with neurocardiologic/autonomic disorders
NCT00748228	N/A	Terminated	22	Studied dopamine-beta-hydroxylase (DBH) genetic variation and its relationship to blood pressure/heart rate response and dietary sodium in orthostatic intolerance

Note: None of the above trials test exogenous dopamine administration as a treatment for POTS; all are mechanistic/physiological studies of the endogenous dopaminergic system in POTS or related autonomic disorders.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29937049	2018	Systematic Review & Meta-analysis	Mayo Clinic Proceedings	Evaluates efficacy of existing POTS treatments overall; provides context for the current lack of clearly beneficial therapies but does not specifically evaluate dopamine
12403667	2002	Observational (clinical) study	Circulation	Found orthostatic intolerance in POTS/NCS occurs without persistent sympathetic neurocirculatory failure, informing cardiac sympathetic dysautonomia mechanisms relevant to dopaminergic signaling
28522107	2017	Observational study	Autonomic Neuroscience: Basic & Clinical	Compared neurohumoral/hemodynamic responses to head-up tilt between high- and normal-norepinephrine POTS subtypes
26608337	2016	Observational study	American Journal of Physiology (Heart & Circ.)	Characterized neurohumoral biomarker profiles in children with orthostatic intolerance to help predict treatment options
32606041	2020	Retrospective case series	Journal of Investigative Medicine	Retrospective review of bupropion (a dopamine/norepinephrine reuptake inhibitor, not dopamine itself) in 47 POTS patients showing symptom improvement
16601453	2006	Review	Current Opinion in Cardiology	Reviews familial/genetic factors in orthostatic tachycardia, including a norepinephrine transporter mutation
12102462	2002	Review	Clinical Autonomic Research	Reviews catecholamine abnormalities including DBH deficiency, which causes elevated dopamine and orthostatic hypotension

EU Market Information

Dopamine currently has no EU marketing authorization on record in this evidence pack (total_licenses: 0, market_status: Not marketed / Not marketed, licenses: []). No product-level authorization details are available for review.

Safety Considerations

Please refer to the SmPC for safety information. All safety fields in this evidence pack (key warnings, contraindications, drug interactions) are marked as data gaps, and the DDI query returned no results (query_status: not_found).

Notably, this evidence pack flags a Blocking-severity data gap (DG001): TFDA/SmPC warning and contraindication labeling is missing, which prevents this candidate from entering initial safety screening (S1). A High-severity gap (DG002) also exists for formal mechanism-of-action data.

Conclusion and Next Steps

Decision: Hold

Rationale:

The predicted indication is supported only by mechanistic/observational human studies of the endogenous renal dopaminergic system in POTS, not by direct interventional evidence that dopamine administration improves POTS symptoms.
A Blocking-severity safety data gap (missing TFDA/SmPC warnings and contraindications) prevents even an initial safety assessment, and the drug has no current EU marketing authorization.

To proceed, the following is needed:

Resolve DG001: obtain and parse the TFDA/SmPC label for warnings and contraindications before any safety screening can proceed
Resolve DG002: query DrugBank API for a complete mechanism-of-action profile
Identify or commission interventional evidence testing dopamine (or dopaminergic agents) specifically as a POTS therapy, rather than as a physiological research probe
Complete a formal DDI screen (current status: not found)
Clarify current regulatory/market status and any historical licensing in EU jurisdictions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.